An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

September 11, 2014

Primary Completion Date

October 1, 2019

Study Completion Date

December 31, 2026

Conditions
Waldenström Macroglobulinemia (WM)
Interventions
DRUG

Acalabrutinib (ACP-196)

DRUG

Acalabrutinib (ACP-196)

Trial Locations (38)

10021

Research Site, New York

11528

Research Site, Athens

13273

Research Site, Marseille

15002

Research Site, Aurillac

20007

Research Site, Washington D.C.

20162

Research Site, Milan

28100

Research Site, Novara

31059

Research Site, Toulouse

34295

Research Site, Montpellier

35000

Research Site, Rennes

37007

Research Site, Salamanca

37203

Research Site, Nashville

40138

Research Site, Bologna

44093

Research Site, Nantes

51092

Research Site, Reims

54500

Research Site, Vandœuvre-lès-Nancy

55404

Research Site, Minneapolis

63003

Research Site, Clermond Ferrand

69495

Research Site, Pierre-Bénite

75015

Research Site, Paris

75651

Research Site, Paris

76022

Research Site, Bedford

77030

Research Site, Houston

78705

Research Site, Austin

80012

Research Site, Aurora

86021

Research Site, Poitiers

93105

Research Site, Santa Barbara

98684

Research Site, Vancouver

1105AZ

Research Site, Amsterdam

2508GA

Research Site, Utrecht

BH7 7DW

Research Site, Bournemouth

LS9 7TF

Research Site, Leeds

LE1 7RH

Research Site, Leicester

NW1 2BU

Research Site, London

SW3 6JJ

Research Site, London

OX3 7LE

Research Site, Oxford

PL6 8DH

Research Site, Plymouth

SO16 6YD

Research Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Acerta Pharma BV

INDUSTRY